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Analysis of reliability of different risk 
classifications for assessment of 
relapses of gastrointestinal stromal 
tumors (GIST) — the impact of primary 
tumor genotyping
ABSTRACT
Background. Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastro-
intestinal tract. Radical surgery is the primary treatment for GIST. Unfortunately, 40–50% of patients relapse, mainly 
due to hepatic and peritoneal metastases. Currently, the treatment of choice for locally advanced, inoperable 
or metastatic GIST is the use of tyrosine kinase inhibitors, including imatinib. GISTs are a group of tumors with 
various morphological, pathological and molecular features as well as different clinical courses, therefore their 
biological course is difficult to determine. Nevertheless, we currently have 5 classifications that assess the risk of 
relapse after surgery. The aim of this study was to analyze prognostic factors with regard to the risk of recurrence 
and overall survival, and to compare the clinical reliability of the recurrence risk classifications developed so far 
with an attempt to present a new classification including the genotype of primary GIST.
Patients and methods. The material consisted of a group of 697 patients with primary GIST treated with the 
intention to cure, collected prospectively as part of the GIST clinical registry, Department of Melanoma and Soft 
Tissue and Bone Sarcomas, Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw. All 
patients were classified based on 5 existing recurrence risk classifications. Univariate and multivariate analysis 
were performed for disease-free survival (DFS) and overall survival (OS). The relationships of the following fac-
tors with DFS and OS were assessed: sex, age, primary tumor mutational status, primary tumor location, primary 
tumor size, number of mitoses/50 HPF, surgical margins and the presence of tumor rupture. The next analysis 
concerned the comparison of the accuracy of existing recurrence risk classifications. The analysis was performed 
using ROC curves and a new classification model was proposed including mutation analysis as well as factors 
such as gender and age for selected existing recurrence risk assessment models.
Results. Univariate and multivariate analyses showed statistical significance of variables such as male sex 
(P = 0.02), mitotic index 5–10/50 HPF and > 10/50 HPF (P < 0.001), primary tumor size 5–10 cm and > 10 cm 
(P < 0.001), primary tumor location outside of the stomach (P < 0.001), R1 surgery (P < 0.001), tumor rupture 
(P < 0.001), and the presence of mutations in the KIT gene exon 11 including deletion 557–558 and the KIT gene 
exon 9 (P = 0.009) as negative prognostic factors affecting disease recurrence. Five-year disease-free survival 
rate was 57.3%. Median DFS was 76 months. Negative prognostic factors for OS are: age < 40 (P = 0.045), 
mitotic index 5–10/50 and > 10/50 HPF (P < 0.001), primary tumor size 5–10 cm and > 10 cm (P < 0.001), 
R1 surgery and tumor rupture (P < 0.001). All existing recurrence risk classifications showed prognostic value 
for assessing differences in DFS and OS, no significant differences were found between individual recurrence 
risk classifications. In addition, the reliability of all these classifications was improved by adding gender, age and 
mutation status. The value added of mutation status for better risk assessment was most significant when used 
in intermediate risk groups according to different classifications (P < 0.01).
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Conclusion. All current GIST recurrence risk classifications allow for reliable assessment of recurrence risk. 
Mutations involving deletions (557–558) in the KIT gene exon 11 are most often present in the group at high risk 
of recurrence. Patients with confirmed mutations in the PDGFRA gene exon 18 and wild-type genotype have 
a favorable prognostic effect. The reliability of existing classifications for assessing the risk of relapse after GIST 
resection can be improved by adding mutation status, especially in groups at intermediate risk of relapse, which 
should facilitate therapeutic decisions in the context of adjuvant therapy.
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Introduction
Gastrointestinal stromal tumors (GISTs) are the 
most common mesenchymal tumors of the gastrointesti-
nal tract. These neoplasms most commonly occur in the 
stomach (40–70%), the small intestine (20–40%) much 
less frequently in the large intestine (5–15%), and rarely 
(> 5%) in the esophagus and intraperitoneally [1–3]. 
The majority of GIST is characterized by the occurrence 
of a mutation activating the KIT protooncogene (about 
70–80%), and the PDGFRA gene that is the platelet-de-
rived growth factor receptor alpha (approximately 
5–15%). The remaining GIST (approximately 15%) is 
the so-called wild type (WT), in which no mutations are 
found in the KIT or PDGFRA genes. A characteristic im-
munochemical marker for GIST is CD117 and a positive 
reaction indicating the presence of this antigen occurs in 
about 95% cases, which is the most important criterium 
in differential diagnosis [2, 4, 5].
At this moment we do not have reliable and clear 
data which would answer the question about the fre-
quency of occurrence and incidence for these tumors, 
but clinically significant cases are calculated at 3–4 per 
million inhabitants per year [6–11].
The basic method of treating GIST is radical resec-
tion based on removing the tumor within the borders 
of healthy tissues. Radical surgery allows for 5-year 
survivals without relapse in 35–65% patients [12–16]. 
Unfortunately, in 40–50% patients after potentially 
therapeutic resection a relapse occurs, mainly in the 
form of metastases to the liver and peritoneum [5, 17]. 
Because of relapses in such a large group of patients 
and the therapeutic success of the low molecular weight 
tyrosine kinase inhibitor (IKT) imatinib monosulphate 
in the therapy of locally non-resectable and/or meta-
static GIST [18–23], adjuvant therapy with imatinib 
was introduced to clinical practice in order to reduce 
disease recurrence/improve patient cures [19, 24–28]. 
These analyses also indicated that the effect of adjuvant 
treatment is associated with the tumor genotype and the 
effectiveness of longer adjuvant treatment with imatinib 
was most clearly seen in the group of GIST patients 
with deletion or insertion/deletion in exon 11 of KIT. 
Of course, it remains to be discussed whether imatinib 
should be used in GIST patients with an intermediate 
recurrence risk and also which of the existing recurrence 
risk classifications should be used, as well as whether ad-
juvant therapy should be used for GIST with genotypes 
with low susceptibility to imatinib [26–28].
GIST is a group of tumors with diverse morphologi-
cal and pathological characteristics and varied clinical 
course [2]. Their biological course is difficult to define 
and as is known from analyses conducted so far it 
depends on several basic criteria: the size and localiza-
tion of the primary tumor and the mitotic index [29]. 
A consensus elaborated by the NIH (National Institutes 
of Health) in the United States in 2001, presented for 
the first time a practical scheme for evaluating the risk 
of a clinical course taking into consideration the size 
of the primary tumor and the mitotic index of GIST 
(Table 1) [13, 30].
The next classification evaluating recurrence risk 
and the tightly associated prognosis for the patients is 
the classification based on the location of the primary 
tumor proposed by Miettinen and Lasota from AFIP 
(Armed Forces Institute of Pathology). They proved by 
analyzing about 1600 GIST cases that large (> 10 cm) 
neoplasms in the stomach with a low mitotic index have 
only a 12% recurrence risk whereas for GIST located in 
the small intestine for similar parameters the recurrence 
risk increases to > 50% [31, 32].
A successive additional negative prognostic factor of 
GIST recurrence risk after resection is perforation of the 
primary tumor (regardless of whether it is spontaneous 
or a result of surgery). This idea became the basis for the 
next classification proposed by Joensuu who modified 
the NIH classification including the neoplasm location 
(stomach vs. other) and tumor perforation as a prog-
nostic factor independent of size and mitotic index. 
Patients with tumor perforation have a high recurrence 
risk due to the possibility of formation of intraperitoneal 
implantation during perforation [33].
One of the last classifications proposed by AJCC 
(American Joint Committee on Cancer) based to a large 
extent on the classification of Miettinen and Lasota was 
presented in January 2010 and the current TNM system 
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Tumor size X X X X X X
Mitotic number X X X X X X
Tumor location  X X X X X
Tumor rupture   X   X
Presence of metastases 
characteristics N and M
   X   
Probable progression 
— ree survival 2 and 
5 years in %
    X  
Addition of mutation      X
was created especially for GIST. This classification di-
vides the localization of the primary tumor into those 
derived from the stomach and others [34, 35].
A nomogram presented at the end of 2009 by Gold 
et al. is the next classification evaluating recurrence risk 
taking into consideration the mitotic index, the size of 
the primary tumor and localization. On the basis of the 
number of points it evaluates and expresses in percent 
the probable survival time (2 and 5 years) without GIST 
recurrence. The nomogram is suggested to better evalu-
ate the recurrence risk in comparison with the NIH clas-
sification and is similar to the classification proposed by 
AFIP Mettienen and Lasota and as the earlier systems 
can be used to qualify patients and to make decision 
on adjuvant treatment [36]. However, it does not take 
possible tumor perforation into consideration and takes 
tumor size as a continuous variable.
Molecular analysis of GIST detected the presence 
of two mutually exclusive mutations in the KIT and 
PDGFRA genes. These mutations cause excessive ex-
pression and activation of the KIT and PDGFRA pro-
tooncogenes. GIST mutations are commonly observed 
in the KIT gene (80–90%) and most of them occur in 
exon 11 and less frequently in exon 9 and sporadically 
in exons 13 and 17. A mutation in the PDGFRA gene is 
less common and is found in about 5 to 10% GIST and 
most often is in exon 18 and less frequently exon 12. In 
about 10–15% GIST no mutations in these two genes 
are observed, they are WT (wild type) [37–40]. Analyses 
performed so far indicate that the presence of mutations 
in the KIT or PDGFRA genes is important for predict-
ing responses to imatinib treatment, moreover the data 
show that a significant role is also played by a mutation 
in a defined exon. Patients with mutations in exon 11 of 
KIT respond better to imatinib treatment while patients 
with mutations in exon 9 are more often resistant to 
therapy with this drug. The results of analyses confirm 
the idea of using a dose of 800 mg/day in patients with 
mutations in exon 9 of KIT [41–43]. 
It seems that determining the type of mutation may 
also be of prognostic significance in primary GIST, 
though at present we do not have data which would al-
low unequivocal confirmation of this idea. Difficulties 
in showing such relations are due to GIST pathogenesis 
as KIT mutations are a very early stage in the formation 
of these neoplasms and cannot be an independent fac-
tor determining an aggressive course of GIST. Several 
investigations have confirmed the association between 
some KIT mutations and a more aggressive course. 
However other analyses confirmed that these mutations 
also occur in very small GIST with a clinically benign 
course [44–46]. The results of analyses performed so far 
suggest further investigations are required in order to 
evaluate the prognostic significance of KIT mutations 
in larger patient groups [47]. There are also suggestions 
that the PDGFRA mutation in the primary tumor occurs 
almost exclusively in GIST originating in the stomach 
and is characterized by a more indolent course of the 
disease [48].
The most important problem after treatment of 
primary GIST is to determine significant and independ-
ent prognostic factors. This statement is important as at 
present we know about at least several clinical and/or 
molecular parameters which can affect the prognosis 
and treatment of GIST patients.
We currently have 5 systems of evaluating the recur-
rence risk for GIST after resection (Table 1), none of the 
proposed systems encompasses the mutation status as 
one of the factors which could affect recurrence risk. An 
attempt to include the mutation status was made during 
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the creation of the TNM AJCC system, but it was finally 
not included because of the small amount of data [34]. 
Determining which of the present systems which 
are used for evaluating risk on the basis of prognostic 
factors is the best for foreseeing recurrence risk so that 
it can be used in clinical practice and whether and if so 
what would be the significance of including the status 
of the mutation in primary GIST is the subject of this 
paper (Table 1).
Material and methods 
The analysis was performed for a group of 697 pa-
tients with primary GIST treated with the intention to 
cure (R0/R1 resection), collected prospectively in the 
Department of Melanoma and Soft Tissue and Bone 
Sarcomas, Maria Skłodowska-Curie National Research 
Institute of Oncology from 2001. The analyzed group 
consisted of 375 (53.8%) women and 322 (46.2%) men, 
treated by radical resection in the years 2001–2011. Data 
about the patients and their treatment were obtained on 
the basis of the analysis of the patients’ medical records 
and data concerning their survival from the National 
Neoplasm Registry. The analyzed group encompassed 
only patients after surgical resection of primary GIST 
without metastases at the moment of diagnosis and with 
a confirmed histopathological analysis. All patients in 
the analyzed group underwent radical (macroscopi-
cally) resection and did not receive adjuvant treatment. 
After resection of the primary GIST the patients were 
subjected to careful medical observation during which 
a physical examination and computer tomography of the 
abdominal cavity and pelvis were performed according 
to recommendations for GIST patients with a high and 
intermediate recurrence risk, every 3–4 months for the 
first 2 years after resection of the primary GIST, and 
subsequently every 6 months until 5 years after the origi-
nal resection and after 5 years once a year in the case of 
resection of a GIST with a low degree of aggressiveness 
[48]. In 291 cases mutations in KIT and PDGRFA genes 
were analyzed. The material for molecular analysis was 
taken from paraffin blocks and/or freshly frozen tumor 
tissue. Molecular analysis was performed for exons 9, 
11, 13, 14 and 17 of the KIT gene and exons 12 and 18 of 
the PDGFRA gene.
All patients were classified based on 5 existing recur-
rence risk classifications. Detailed clinical, pathological 
and molecular data are presented in Table 2.
Statistical analysis
The analyzed patients were observed from 2001 (date 
associated with the creation of the Clinical GIST Re-
gistry) until August 2013. The final date of the surgery 
of the patients included in the analysis was December 
2010. The frequency of recurrence was evaluated on 
the basis of computer tomography during the period of 
observation. Disease-free survival (DFS) was calculated 
from the date of GIST resection to the date of local 
recurrence, date of distant metastases or date of the 
last observation. Overall survival (OS) was calculated 
from the resection to the date of the last observation or 
the date of death.
Univariate analysis was performed overall survival 
and for disease-free survival using Kaplan-Meier and 
the log-rank test (univariate analyses). Survival of the 
patients was expressed in the form of probability of 
death during 5 years from the operation (with a 95% 
confidence interval) and graphically on figures showing 
survival curves. In order to identify independent vari-
ables affecting the patients’ survival a multivariate Cox 
model was used. Significant variables were selected by 
a progressive stepwise approach. The results are pre-
sented as a hazard ratio (HR) with a 95% confidence 
interval. In the next step of the analysis using methods 
of logistic regression, a model was constructed in which 
probability of disease-free survival and overall survival 
was estimated for 1 and 5 years. We checked whether 
taking the mutation code into consideration significantly 
improved the predictive abilities of the model. To mo-
dels selected a priori variables signifying the mutation 
code were added and then ROC curves were constructed 
and then ROC curves constructed on the basis of values 
calculated from the models were compared. The same 
method was used to compare different classifications. 
The calculations were performed using the software 
package R 3.0.1 (R Core Team (2013). R: A language 
and environment for statistical computing. R Founda-
tion for Statistical Computing, Vienna, Austria. URL 
http://www.R-project.org/), the survival package (Ther-
neau T (2013). _A Package for Survival Analysis in S_. 
R package version 2.37-4, URL: http://CRAN.R-project.
org/package=survival) and pROC (Xavier Robin, Nata-
cha Turck, Alexandre Hainard, Natalia Tiberti, Frédé-
rique Lisacek, Jean-Charles Sanchez and Markus Müller 
(2011). pROC: an open-source package for R and S+ to 
analyze and compare ROC curves. BMC Bioinformatics, 





The basic evaluated parameter was disease-free 
survival (DFS). During the observations, 265 (38.3%) 
recurrences were observed. Median disease-free survival 
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Table 2. Characteristics of the analyzed patients
Characteristic Number (%)
Sex Women 375 (53.8%)
Men 322 (46.2%)
Age at diagnosis (years) < 40 62 (8.9%)
41–65 422 (60.6%)
> 65 213 (30.5%)
Localization Stomach 373 (53.5%)
Duodenum 36 (5.2%)
Small intestine 237 (34.0%)
Large intestine/rectum 25 (3.6%)
Other 26 (3.7%)
Size of primary tumor [cm] < 5 266 (39.1%)
> 5–10 254 (37.4%)
> 10 160 (23.5%)
No data 17 (2.4%)
Number of mitoses in 50 visual fields  
at large magnification
≤ 5 401 (63%)
> 5–10 98 (15.4%)
> 10 138 (21.7%)
No data 60 (8.6%)
Surgical margins R0 554 (80.4%)
R1 135 (19.5%)
No data 8 (1.1%)
Tumor rupture No 596 (92.5%)
Yes 48 (7.5%)
No data 53 (7.6%)
Mutation analysis KIT 11 deletion 557–558 65 (22.3%)
KIT 11 point mutation or insertion 63 (21.6%)
KIT 11 other deletions 45 (15.5%)
KIT 9 23 (7.9%)
PDGFRA 18 D842V 25 (8.6%)
Other PDGFRA mutations 21 (7.2%)
Other KIT mutations 11 (3.8%)
Wild type (WT) — no KIT or PDGFRA mutations 38 (13.1%)
No data 406 (58.2%)
Recurrence risk according to NIH (National 
Institutes of Health Classification)




No data 41 (5.9%)
Æ
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Characteristic Number (%)




No data 33 (4.7%)
Recurrence risk according to Miettinen  
and Lasota (AFIP-NCCN)




No data 58 (8.3%)
Recurrence risk according to AJCC Tumor stage I 281 (40.3%)
Tumor stage II 115 (16.5%)
Tumor stage IIIA 79 (11.3%)
Tumor stage IIIB 160 (23.0%)
No data 62 (8.9%)
Recurrence risk within 2 years according  





No data 97 (13.9%)






No data 97 (13.9%)
was 76 months. In Table 3 univariate analysis for par-
ticular variables which could affect disease recurrence is 
presented. The variables for which statistical significance 
was demonstrated were: male sex (P = 0.02), mitotic 
index 5–10/50 HPF and > 10/50 HPF (P < 0.001), size 
5–10 cm and > 10 cm (P < 0.001), localization outside the 
stomach (P < 0.001), extent of surgery R1 (P < 0.001), 
tumor rupture P < 0.001), and presence of a mutation in 
the KIT gene in exon 11 encompassing the 557–558 dele-
tion an in the KIT gene in exon 9 (P = 0.009). 
Overall survival
The next parameter evaluated during the analysis 
was overall survival (OS) estimated by the Kaplan-Meier 
method. 118 (17.2%) of the patients died and the OS 
median was not attained.
Based on univariate analysis, the following fac-
tors were found to have a negative effect on OS: the 
number of mitoses > 10/HPF (P < 0.001), size of the 
primary tumor > 10 cm (P < 0.001), surgical mar-
gins R1 (P = 0.004), tumor rupture (P < 0.001) and 
age < 40 (P = 0.045). Detailed results for individual 
variables are presented in Table 4.
Multivariate analyses
In order to identify independent variables affecting 
progression-free survival and overall survival of the 
patients, Cox’s multiparameter model was used. Signifi-
cant variables were selected by the progressive stepwise 
approach. 2 models were constructed: the first one for 
variables without adding the mutations and the second 
Table 2 cont. Characteristics of the analyzed patients
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Table 3. Results of univariate analysis for disease-free survival (DFS)







Sex Women 372 59.7 (53.7–66.5) 0.024
Men 320 54.2 (48.1–61.1)
Age (years) < 40 61 56.6 (44.0–72.8) 0.389
41–65 421 55.9 (50.4–62.0)
> 65 210 60.3 (52.4–69.5)
Localization Stomach 370 74.5 ( 69.3 - 80.2) < 0.001
Duodenum 36 48.5 (31.8–73.9)
Small intestine 236 41.7 (35.0–49.6)
Large intestine/rectum 24 45.8 (28.1–74.7)
Other 26 17.4 (5.5–55.0)
Size of primary tumor [cm] < 5 263 86.2 (79.8–93.1) < 0.001
> 5–10 253 55.2 (48.5–62.7)
> 10 169 27.8 (21.1–36.5)
No data 17 41.8 (22.8–76.6)
Number of mitoses in 
50 visual fields (mitotic 
index, MI)
≤ 5 398 80.2 (75.3–85.4) < 0.001
> 5–10 98 44.5 (33.8–58.5)
> 10 138 16.8 (10.8–26.0)
No data 58 46.4 (33.8–63.8)
Surgical margins (R0, R1) R0 551 63.2 (58.4–68.4) < 0.001
R1 133 34.7 (26.3–45.7)
No data 8 55.6 (23.1–100.0)
Tumor rupture No 592 60.9 (56.3–65.9) < 0.001
Yes 48 24.3 (13.8–43.0)
No data 52 45.3 (26.4–78.0)
Mutation evaluation  KIT 11 deletion 557–558 65 35.1 (23.8–51.8) 0.009
KIT 11 PM/INS 63 59.2 (46.5–75.4)
KIT 11 other deletions 45 50.4 (35.5–71.6)
KIT 9 23 38.5 (21.2–69.9)
PDGFRA 18 D842V 25 83.6 (68.2–100.0)
Other mutations of the PDGFRA gene 21 87.8 (73.4–100.0)
Other mutations of the KIT gene 10 50.6 (24.6–100.0)
Wild type (WT) 38 44.3 (29.5–66.6)
No data 402 61.2 (55.4–67.6)
Recurrence risk evaluation 
according to NIH 
(National Institutes of 
Health Classification)
High 302 30.8 (25.5–37.2) < 0.001
Intermediate 150 79.3 (71.5–88.0)
Low 169 94.7 (88.9–100.0)
Very low 31 100 (100.0–100.)
No data 40 55.7 (40.0–77.5)
Æ
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Recurrence risk evaluation 
according to Joensuu
High 354 34.2 (29.1–40.3) < 0.001
Intermediate 98 90.2 (83.9–96.9)
Low 207 94.1 (88.9–99.7)
No data 33 68.2 (52.7–88.3)
Recurrence risk evaluation 
according to Miettinen  
and Lasota (AFIP-NCCN)
High 254 25.6 (20.1 – 32.6) < 0.001
Intermediate 105 66.9 (57.0–78.5)
Low 133 89.7 (83.0–96.8)
Very low 151 95.4 (91.0–99.9)
No data 58 48.4 (35.3–66.5)
Recurrence risk evaluation 
according to AJCC
Tumor stage I 277 93.8 (89.8–97.9) < 0.001
Tumor stage II 115 68.7 (59.2–79.7)
Tumor stage IIIA 79 34.4 (24.2–48.9)
Tumor stage IIIB 160 20.4 (14.5–28.8)
No data 61 45.4 (33.1–62.3)
Recurrence risk evaluation 
within 2 years according  
to Gold’s nomogram 
(1,28) 155 22.7 (16.5–31.3) < 0.001
(28,83) 154 58.1 (49.4–69.4)
(83,96) 169 85.5 (78.8–92.8)
(96,98) 119 96.9 (92.7–100.0)
No data 95 39.4 (29.4–52.9)
Recurrence risk evaluation 
within 5 years according  
to Gold’s nomogram
(1,8) 155 22.7 (16.5–31.3) < 0.001
(8,68) 153 58 (49.2–68.2)
(68,91) 147 83.3 (75.7–91.7)
(91,96) 142 97.4 (93.9–100.0)
No data 95 39.4 (29.4–52.9)
      
Table 3 cont. Results of univariate analysis for disease-free survival (DFS)
one with the mutations added. Risk classification was 
not taken into consideration in multivariate analyses as 
they link individually analyzed parameters.
The factors with a negative effect on the probability 
of disease recurrence in the Cox regression analysis 
were: the mitotic index > 5/50 HPF, localization of 
the primary tumor outside the stomach, the size of the 
primary tumor > 5 cm and the male sex (Table 5). 
In the model taking the GIST genotype into con-
sideration the negative factors were the presence of 
a mutation other than in PDGFRA, the mitotic in-
dex > 5/50 HPF, male sex and the size of the primary 
tumor > 5 cm (Table 6). Similar results were obtained 
for the evaluation of factors affecting OS (Table 7).
Comparison of the accuracy of classification  
of GIST recurrence risk 
The comparison of the existing recurrence risk clas-
sifications was performed using ROC curves. They were 
compared in the context of 5-year DFS and also 5-year 
OS. None of the statistically significant differences were 
found between individual classifications both for 5-year 
DFS and for 5-year OS. 
The comparison of the prognostic value of recur-
rence risk for 5-year DFS is presented in Figures 1–3.
All analyses indicate a lack of statistically significant 
differences between individual risk classifications, the 
graphs are nearly identical. This is due to the fact that 
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Table 4. Results of univariate analysis for overall survival (OS)




95% confidence  
interval
p
Sex Women 369 87.3 (83.0–91.8) 0.141
Men 318 83.7 (78.8–88.9)
Age < 40 61 88.3 (79.9–97.6) 0.045
41–65 417 86.8 (82.9–91.0)
> 65 209 81.5 (74.5–89.0)
Localization Stomach 367 89.1 (84.9–93.4) 0.06
Duodenum 36 81.2 (67.2–98.2)
Small intestine 234 84.1 (78.7–89.9)
Large intestine/rectum 24 79.9 (64.0–99.7)
Other 26 74.3 (56.8–97.0)
Size of primary  
tumor
< 5 261 99.5 (98.5–100.0) < 0.001
> 5–10 252 82.9 (77.4–88.7)
> 10 157 75.6 (68.5–83.5)
No data 17 84.6 (67.1–100.0)
Number of mitoses  
in 50 visual fields  
(mitotic index MI/HPF)
≤ 5 395 92.8 (83.3–96.4) < 0.001
> 5–10 98 87.2 (79.5–95.7)
> 10 136 68.8 (60.5–78.3)
No data 58 85.1 (75.5–96.0)
Surgical margins (R0, R1) R0 545 89.3 (86.0–92.7) 0.004
R1 134 72.1 (63.6–81.8)
No data 8 100 (100.0–100.0)
Tumor rupture No 588 86.6 (83.2–90.2) 0.005
Yes 48 81.4 (69.6–95.2)
No data 51 76.9 (62.1–95.2)
Mutation evaluation KIT 11 deletion 557–558 65 81.8 (70.0–94.3)
0.75
KIT 11 PM/INS 62 87 (77.7–97.5)
KIT 11 other deletions 45 86.6 (75.1–99.9)
KIT 9 23 87.7 (73.0–100.0)
PDGFRA 18 D842V 25 82 (65.1–100.0)
Other mutations of the PDGFRA
gene
21 87.4 (72.4–100.0)
Other mutations of the KIT gene 10 87.5 (67.3–100.0)
Wild type (WT) 37 66.4 (51.3–86.0)
No data 399 88.5 (84.5–92.6)
Æ
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Table 4 cont. Results of univariate analysis for overall survival (OS)




95% confidence  
interval
p
Recurrence risk  
evaluation according  
to NIH (National Institute  
of Health Classification)
High 299 75.7 (70.4–81.4) < 0.001
Intermediate 150 97.5 (94.0–100.0)
Low 166 100 (100.0–100.0)
Very low 32 100 (100.0–100.0)
No data 40 82 (68.6–97.9)
Recurrence risk evaluation 
according to Joensuu
High 351 78.4 (73.6–83.5) < 0.001
Intermediate 98 98.6 (96.0–100.0)
Low 205 99.2 (97.5–100.0)
No data 33 84 (70.5–99.9)
Recurrence risk evaluation 
according to Miettinen  
and Lasota (AFIP-NCCN)
High 243 76.5 (70.6–82.9) < 0.001
Intermediate 104 89.5 (82.7–96.9)
Low 133 98.9 (96.9–100.0)
Very low 149 96 (91.4–100.0)
No data 58 78.9 (70.5–99.9)
Recurrence risk evaluation 
according to AJCC
Tumor stage I 275 98.9 (97.3–100.0) < 0.001
Tumor stage II 114 91 (84.7–97.8)
Tumor stage IIIA 78 75.9 (65.8–87.6)
Tumor stage IIIB 159 73.5 (66.1–81.8)
No data 61 83 (72.8–94.6)
Recurrence risk evaluation 
within 2 years according  
to Gold’s nomogram
[1,28) 154 75.2 (67.9–83.4) < 0.001
[28,83) 153 85.9 (79.5–92.8)
[83,96) 167 95 (90.7–99.6)
[96,98] 118 100 (100.0–100.0)
No data 95 80.4 (71.6–90.3)
Recurrence risk evaluation 
within 5 years according  
to Gold’s nomogram
[1,8) 154 75.2 (67.9–83.4) < 0.001
[8,68) 152 85.9 (79.4–92.8)
[68,91) 145 94.4 (89.4–99.6)
[91,96] 141 100 (100.0–100.0)
No data 95 80.4 (71.6–90.3)
all classifications include the most significant prognos-
tic factors.
New classification model including mutation 
analysis for progression-free survival
In the next step of the analysis using logistic regres-
sion, a model was constructed in which probability of 
survival for 1 and 5 years was calculated. The effect of 
including the mutation code on the predictive value of 
the model was tested. Variables marking the mutation 
code were added to models selected a priori, and then 
ROC curves were prepared on the basis of predicted val-
ues calculated from the models. The analysis indicated 
that adding variables such as sex, age and mutation status 
to the existing classifications improved their reliability. 
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Table 5. Results of multivariate analysis of factors affecting DFS
Characteristic HR 95% CI P
Sex Women 1    
Men 1.3 (0.99–1.71) 0.6
Age < 40 1    
41–65 1.21 (0.76–1.95) 0.42
> 65 1.13 (0.68–1.88) 0.64
Localization Duodenum 1    
Small intestine 0.79 (0.45–1.4) 0.43
Large intestine/rectum 0.97 (0.42–2.23) 0.94
Stomach 0.5 (0.28–0.88) 0.02
Other 1.09 (0.51–2.34) 0.83
Tumor size < 5 1    
> 5–10 3.36 (2.09–5.4) 0
> 10 6.25 (3.84–10.18) 0
Number of mitoses in 50 visual fields  
(mitotic index MI/HPF)
≤ 5 1    
> 5–10 2.86 (1.95–4.19) 0
> 10 5.08 3.67–7.01) 0
Table 6. The results of multiparameter analysis of factors affecting DFS including the type of mutation
Characteristic HR 95% CI P
Sex Women 1    
Men 1.62 (1.07–2.46) 0.02
Age < 40 1    
41–65 1.67 (0.89–3.15) 0.11
> 65 1.46 (0.71–3.02) 0.31
Localization Duodenum 1    
Small intestine 0.98 (0.29–3.34) 0.98
Large intestine/rectum 1.26 (0.31–5.03) 0.75
Stomach 0.93 (0.27–3.15) 0.9
Other 1.24 (0.3–5.13) 0.76
Tumor size < 5 1    
> 5–10 2.12 (1.08–4.18) 0.03
> 10 5.86 (2.84–12.07) 0
Number of mitoses in 50 visual fields  
(mitotic index MI/HPF)
≤ 5 1    
> 5–10 3.07 (1.69–5.58) 0
> 10 4.38 (2.61–7.36) 0
Genotype (mutation evaluation) KIT 11 deletion 557–558 1    
KIT 11 PM/INS 1.03 (0.58–1.81) 0.92
KIT 11 other deletions 1.13 (0.63–2.03) 0.69
KIT 9 1.38 (0.68–2.77) 0.37
PDGFRA 18 D842V 0.41 (1.14–1.23) 0.05
Other mutations of the PDGFRA gene 0.61 (0.18–2.13) 0.44
Other mutations of the KIT gene 0.76 (0.26–2.25) 0.63
Wild type (WT) 1.66 (0.86–3.21) 0.13
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Table 7. The results of the multiparameter analysis of factors affecting OS including the type of mutation
Characteristic HR 95% CI P
Age < 40 1    
41–65 2.84 (0.89–9.06) 0.08
> 65 6.23 (1.83–21.26) 0
Tumor size < 5 1    
> 5–10 4.81 (1.1–20.95) 0.04
> 10 7.31 (1.67–31.97) 0.01
Number of mitoses in 50 visual fields  
(mitotic index MI/HPF)
≤ 5 1    
> 5–10 1.91 (0.79–4.62) 0.15
> 10 3.2 (1.64–6.24) 0
Genotype (mutation evaluation) KIT 11 deletion 557–558 1    
KIT 11 PM/INS 0.89 (0.37–2.15) 0.79
KIT 11 Other deletions 0.84 (0.34–2.09) 0.71
KIT 9 1.12 (0.43–2.92) 0.82
PDGFRA 18 D842V 2 (0.55–7.34) 0.3
Other mutations of the PDGFRA gene 1.4 (0.3–6.64) 0.67
Other mutations of the KIT gene 0.85 (0.11–6.7) 0.88
Wild type (WT) 2.59 (1.13–5.96) 0.03
Figure 1. The prognostic value of the Miettinen and Lasota AFIP-
NCCN (ML) classification in comparison to National Institutes 
of Health (NIH) in comparing recurrence risk within 5 years
Figure 2. The prognostic value of the Miettinen and Lasota 
AFIP-NCCN (ML) classification in comparison to Nomogram 
5 in comparing recurrence risk within 5 years
Moreover, the addition of the mutation status was the 
most significant in groups with intermediate risk in 
individual classifications (Figures 4–9). 
In groups with intermediate risk a model taking 
into consideration sex, age and additionally the type of 
mutation is the closest to reality (Figures 7–9).
Discussion
The evaluation of recurrence risk after surgical 
treatment of GIST is very important in the context of 
adjuvant treatment and planning control examinations 
during observation after surgery [49]. The present clas-
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Figure 3. The prognostic value of the National Institutes of 
Health (NIH) classification in comparison to Nomogram 5 in 
comparing recurrence risk within 5 years
sifications of recurrence risk based on such factors as 
tumor size, localization, mitotic index and tumor rupture 
allow reliable estimation of recurrence risk and are used 
in clinical practice [50, 51]. In recent years mutation 
status as a factor affecting recurrence risk has also been 
discussed [49, 51, 52].
In the presented group of patients, the basic evalu-
ated parameter was disease-free survival DFS. During 
the observations, 265 (38.3%) of disease recurrences 
were observed. It should be stressed that the analyzed 
group consisted of patients not receiving imatinib adju-
vant therapy after tumor resection, thus DFS represents 
the natural course of the disease. Median disease-free 
survival was 76 months. Other authors obtained similar 
results [17, 53, 54]. The following prognostic factors 
Figure 4. Model taking into consideration: sex, age and 
classification according to AJCC
Figure 5. Model taking into consideration: sex, age and 
classification according to NIH
Figure 6. Model taking into consideration: sex, age and 
classification according to Joensuu (J)
were found to be statistically significant in the present 
analysis: mitotic index 5–10/50 HPF and > 10/50 HPF 
(P < 0.001), size 5–10 cm and >10 cm (P < 0.001), 
MI > 5/50 HPF and tumor size > 5 cm are associated 
with a much shorter disease-free survival, which has 
also been demonstrated in all previous analyses [55–58]. 
The results of the analysis also confirm the effect of 
the tumor location for prognosis in GIST, which is in 
agreement with the results of other investigations [31, 
32, 55–57, 59]. Localization of GIST outside the stomach 
(mainly in the intestine) gives a much worse prognosis 
than GIST localized in the stomach which has been 
reflected in the classification modified by Mietinnenn 
and Lasota [57, 59]. At present these factors are the basis 
of existing classifications, including the TNM staging 
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Figure 9. Model taking into consideration: sex, age and 
classification according to Joensuu (J) in an intermediate risk group
Figure 7. Model taking into consideration: sex, age and 
classification according to AJCC in an intermediate risk group
Figure 8. Model taking into consideration: sex, age and 
classification according to NIH in an intermediate risk group
according to AJCC. The presented relationships also 
confirm that the group of patients with primary GIST 
is representative. Other factors which significantly in-
crease GIST recurrence risk are the extent of resection 
R1 (P < 0.001), tumor rupture (P < 0.001), male sex 
(P = 0.02). Radical resection (R0) in the microscopic 
evaluation and lack of tumor rupture regardless of 
whether spontaneous or linked to surgery, is extremely 
important during GIST surgery. Tumor rupture, regard-
less of tumor size and mitotic index, is a factor placing 
the patients in a high recurrence risk group according 
to the NIH classification modified according to Joensuu 
[33, 59–61]. The presented results also indicate an as-
sociation between male sex and recurrence risk. Male 
sex in the analyzed group was a negative prognostic 
factor. Data from the literature concerning this factor 
are not as unequivocal as those presented above [56, 
58]. All the above-mentioned factors (with the exception 
of resection R1) are statistically significant in uni- and 
multivariate analysis. So far only a few papers have ana-
lyzed the prognostic significance of the genotype of the 
primary tumor in patients with GIST, as many more were 
focused on the predictive role of mutations in response 
to treatment with tyrosine kinase inhibitors [62–64]. The 
next factor important for evaluation is the presence of 
a mutation in exon 11 of the KIT gene encompassing 
deletion 557–558, which turned out to be a factor asso-
ciated with short disease-free survival time. In the light 
of available data, this mutation most commonly occurs 
in tumors originating outside the stomach, > 5 cm and 
with MI > 5/50 HPF, which automatically qualifies the 
patients for the high recurrence risk group and should 
be an additional factor in qualification for adjuvant 
treatment with imatinib [65], moreover, the present data 
unequivocally indicate that this is the mutation which is 
the most sensitive to imatinib [66–68]. The results of the 
univariate analysis indicate that the presence of an exon 
9 mutation in the KIT gene also significantly shortens the 
time to disease recurrence. Summing up, the presence 
of a mutation in the KIT gene, regardless of whether it 
is in exon 11 encompassing deletion 557–558 or exon 
9 (P = 0.009), is associated with a shorter DFS, com-
paring to a mutation in the PDGFR gene where the 
estimated 5-year disease-free survival with a mutation 
in exon 11 encompassing deletion 557–558 is 35.1% 
(95% CI: 23.8–51.8%) or exon 9 — 38.5% (95% CI: 
21.2–69.95) vs. 83.6% (95% CI: 68.2–100.0) in the pres-
ence of a mutation in the PDGFRA gene. Longer DFS 
for GIST with a PDGFRA mutation has already been 
presented by other authors [69, 70]. The first papers at 
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the end of the 20th beginning of the 21st century only 
indicated that patients with GIST with a KIT mutation 
have more aggressive forms of the tumor than patients 
without the mutation, or with a mutation in the PDG-
FRA gene but the types of mutations were not analyzed 
in detail [38, 71, 72]. A Spanish group [73] was the 
first to observe the negative prognostic significance of 
a deletion encompassing codon 557 and/or 558 of the 
KIT gene. DeMatteo and co-authors also suggested 
that specific KIT mutations can have a prognostic value 
in univariate, but not multivariate analysis [68, 74] 
— indicating that GIST with a point mutation or a KIT 
insertion can have a better clinical course than exon 
9 KIT mutations or deletions encompassing amino acids 
W557 and/or K558 of KIT, whereas tumors without KIT 
mutations are associated with an intermediate progno-
sis. The presented work is a confirmation of these fac-
tors as independent prognostic biomarkers for a much 
larger group of patients. The biological basis of these 
associations has not been explained but it is suggested 
that the mutated form of the KIT protein generated by 
substitution of proline for lysine in position 558 leads to 
ahigher constitutive phosphorylation of the receptor and 
greater cellular proliferation [75]. Several papers have 
also indicated a more favorable course of the disease in 
patients with primary GIST with a PDGFRA mutation 
(especially in exon 18, occurring mainly in tumors with 
a stomach localization and interestingly with a point 
mutation D842V characterized by resistance to used 
tyrosine kinase inhibitors in the case of nonresect-
able/metastatic tumors) [39, 46, 70, 76–78], this was also 
confirmed by the analysis of trial ACOSOG Z9001 in 
the placebo group [68]. 
On the basis of univariate analysis the following 
factors were found to have a negative effect on OS: 
the number of mitoses > 10/HPF (P < 0.001), size 
of primary tumor > 10 cm (P < 0.001). surgical mar-
gins R1 (P = 0.004), tumor rupture (P < 0.001) and 
age < 40 (P = 0.045). These factors, with the exception 
of surgical margins, were also found to be statistically 
significant in multivariate analysis. In the presented 
analysis no significant effect of mutation status on OS 
was observed. The analysis of factors affecting OS, after 
resection of the primary GIST, is one of the few in the 
literature and indicates significantly good survival even 
in high-risk groups which is associated with the high 
activity of imatinib and other tyrosine kinase inhibitors 
used to treat the recurrence of this disease [14, 79]. The 
currently used adjuvant therapy imatinib after resection 
of high-risk GIST can be expected to contribute to fur-
ther improvement of the patients’ survival.
Analysis of existing classifications of recurrence 
risk (expressed as ROC curves) for 5-year DFS and 
OS confirmed the prognostic significance of these 
classifications. The presented results demonstrate that 
the currently available and used classifications allow 
a reliable evaluation of recurrence risk, which is in 
agreement with the results from other authors [80–82]. 
No statistically significant differences were found when 
comparing particular classifications. This may be due to 
the fact that each of them encompasses two characteri-
stics, tumor size and the number of mitoses, which as 
has also been demonstrated in the present analysis are 
the most important risk factors. Of course, each of the 
classifications has limitations, and the results of Goh et 
al. (2008) indicate that the AFIP classification of Miet-
tinen and Lasota is better at predicting recurrence in 
comparison with NIH, which is due to the addition of the 
criterion of tumor localization, which as has been proved 
also in this analysis is an unfavorable prognostic factor 
for tumors localized outside the stomach. At the same 
time, the application of a division into low and very low 
recurrence risk appears to be insignificant in the context 
of deciding about adjuvant treatment and the planned 
scheme of control visits, which is also reflected in the 
present analysis where no statistically significant differ-
ence was found between low and very low recurrence 
risk both for DFS and OS. Similar results of analyses are 
also presented by other authors [51]. In the literature, it 
is difficult to find a comparison of all the current existing 
classifications. In the analysis performed by Yanagi-
moto et al. comparing NIH, AFIP, NIH according to 
Joensuu, AJCC and „Japanese modified NIH”, where 
tumor rupture and/or organ infiltration were added in 
a group of 712 patients, the NIH classification according 
to Joensuu was found to be the most sensitive in predict-
ing GIST recurrence. On the basis of this analysis, the 
NIH classification was selected for qualifying patients 
for adjuvant treatment [69]. However, this analysis did 
not take into consideration mutation analysis nor the 
nomogram according to Gold.
None of the papers published so far has attempted 
to include mutation analysis in the prognostic system 
after resection of primary GIST. The results presented in 
this paper unequivocally demonstrate an improvement 
in the prognostic accuracy of risk classification after 
including genotyping in addition to classical prognostic 
factors — this can affect the proper classification of 
patients with intermediate recurrence risk for adjuvant 
treatment with imatinib after resection of the primary 
tumor. The paper by Wozniak et al. encompassing 
multicenter clinical, pathological and molecular data 
of patients with localized GIST after resection collected 
in the database European ConticaGIST confirms the 
favorable prognostic significance of the exon 18 PDG-
FRA mutation and the negative effect of duplication in 
exon 9 of KIT (occurring mainly in the small intestine) 
and deletion 557–558 in exon 11 of KIT. Interestingly, 
according to the authors of that paper, the presence of 
a deletion encompassing codons 557 and/or 558 of KIT 
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was a significant, independent negative prognostic factor 
only for GIST originating in the stomach. The authors 
state that the presence of this genetic perturbation in 
patients with GIST derived from the stomach even with 
a theoretically lower risk evaluated on the basis of ex-
isting classifications should be an additional indication 
for adjuvant treatment with imatinib. In the presented 
work a statistical significance (P < 0.001) was also 
found for the presence of mutations in particular risk 
groups with an unfavorable indication for the high-risk 
group. Over 40% of all determined mutations are 
mutations determined in tumors which were evaluated 
as a high-risk group, moreover, an exon 11 deletion in 
KIT (W557–K558) is the most common mutation in the 
group with high recurrence risk. Because of the size of 
the examined group it was not possible to conduct such 
a detailed analysis of subgroups of patients depending 
on the localization as had been done by the ConticaGIST 
group. In the newest extended analysis by the Contica-
GIST research team of a group of 1844 patients where 
the most common types of mutations were analyzed 
two prognostic classes were distinguished: class 1 (C1, 
good prognosis), this group included mutations of exon 
11 of KIT, duplications, deletions with the exception of 
codons 557–558 and exon 18 of PDGFRA 18, whereas 
class 2 (C2, poor prognosis) encompassed deletions of 
codons 557–558 of KIT exon 11. When in a multivariate 
model the correlation between tumor localization and 
the mutation status were taken into consideration an 
unfavorable effect of tumor size > 10 cm, mitotic index 
6–10 > 10/50 HPF, were observed but class 2 mutations 
gave a poorer prognosis only in the case of stomach tu-
mors in contrast to GIST localized outside the stomach 
[83]. Even though the group analyzed in the present 
work is smaller and the evaluation of the mutation type 
was not as precise, similar conclusions can be drawn 
from the results — a tumor localized in the stomach and 
the presence of a KIT mutation in codons 557–588 is 
a poor prognostic factor and should be important in 
updating the current classifications of recurrence risk. 
Similar conclusions were reached by the authors on 
an analysis of a group of 451 patients, during which mul-
tivariate Cox regression models allowed three molecular 
risk groups to be identified: group I had the best result 
and encompassed mutations of exon 12 of PDGFRA, 
a BRAF mutation and exon 13 KIT mutations; group II, 
with an intermediate clinical phenotype (HR = 3.06), 
encompassed triple-negative cases, mutations in exon 
17 of KIT, codon D842V in exon 18 of PDGFRA and 
in exon 14 PDGFRA; group III had the poorest result 
(HR = 4.52) and encompassed mutations in exon 9 of 
KIT and exon 11 of KIT and in exon 18 of PDGFRA 
other than D842V. The mutation was a significant prog-
nostic factor for overall survival in localized GIST not 
subjected to systemic treatment (P < 0.001): in patients 
with a KIT mutation the results were worse than in the 
case of a PDGFRA mutation or triple-negative (wild 
type KIT, PDGFRA, BRAF). This analysis underlines 
the prognostic effect of mutation status on the natural 
course of GIST and suggests that molecular prognostic 
grouping can supplement clinical stratification criteria 
when making decisions on adjuvant treatment and 
responds to the question whether the mutation status 
affects the prognosis of localized untreated GIST [84].
The Scandinavian Sarcoma Group performed an 
analysis aimed at determining the effects of KIT and 
PDGFRA mutations on recurrence-free survival (RFS) 
in patients with GIST treated by surgery and with 
imantinib adjuvant treatment. 400 patients treated by 
resection in whom recurrence risk was evaluated as 
high were included in the analysis. They were divided 
into 2 groups receiving imatinib for one or 3 years. The 
end-point was disease-free survival. The mutations 
were grouped according to the gene and exon. Muta-
tions in exon 11 of KIT were then grouped into deletion 
mutations or insertion-deletion mutations, substitution 
mutations, insertion or duplication mutations and muta-
tions encompassing codons 557 and/or 558. Mutations in 
PDGFRA and insertion or duplication mutations in exon 
11 of the KIT gene were linked with a favorable DFS, 
whereas mutations in exon 9 of the KIT gene were associ-
ated with an unfavorable outcome. Patients with a dele-
tion in exon 11 of the KIT gene or an insertion/deletion 
mutation had a better DFS when they were assigned 
to a 3-year group in comparison with a one year group 
(5-year RFS 71.0% vs. 41.3%; P < 0.001), whereas a lack 
of positive effects of 3-year treatment was observed in 
other examined mutation subgroups. Deletion muta-
tions in exon 11 of the KIT gene, deletions encompassing 
codons 557 and/or 558 were linked with short DFS in the 
one year group but not in the 3-year group. The results 
of the analysis presented above confirm that the benefits 
for patients from adjuvant treatment depend on the type 
of occurring mutation. Patients included in the analy-
sis in whom deletion mutations in exon 11 of the KIT 
gene were confirmed profited the most from a longer 
duration of adjuvant treatment with imatinib. Thus the 
time of adjuvant treatment with imatinib modifies the 
risk of GIST recurrence linked to some KIT mutations 
including deletions, which affect the codons 557 and/or 
558 [85] of exon 11.
Conclusions
In this analysis the most important prognostic factors 
linked to disease-free survival were found to be: tumor 
size, mitotic index, localization outside the stomach and 
the presence of a mutation in exon 11 of the KIT gene 
encompassing deletion 557–558 and in exon 9 of the 
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same gene. The factors which significantly affect overall 
survival are: number of mitoses > 10/HPF (P < 0.001), 
size of primary tumor > 10 cm (P < 0.001), surgical 
margins R1 (P = 0.004), tumor rupture (P < 0.001) 
and age < 40 (P = 0.045). Over 40% of all determined 
mutations were determined in tumors which were clas-
sified into the high-risk group, moreover, mutations 
encompassing deletion (557–558) in exon 11 of the 
KIT gene are most commonly present in the group with 
a high recurrence risk which should cause initiation of 
adjuvant therapy. The presence of a mutation in exon 
18 of PDGFRA has a favorable prognostic significance in 
GIST after resection of the primary tumor. All presently 
used classifications of evaluation of GIST recurrence 
risk allow a reliable evaluation of this risk. The reliability 
of the existing classifications of GIST recurrence after 
resection can be improved by including the mutation 
status especially in groups with intermediate recurrence 
risk. The use of treatment molecularly directed at the 
presence of a specific mutation appears to be critical 
not only in the context of adjuvant treatment but also 
in the treatment of advanced and/or metastatic disease.
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